AACR Annual Meeting | Conference

AFM13 Showcases 100% ORR in Relapsed/Refractory CD30+ Hodgkin Lymphoma

April 13th 2021

AFM13, an innate cell engager, demonstrated an objective response rate of 100% in adult patients with CD30-positive, relapsed/refractory Hodgkin lymphoma.

Multi-Omics Approach to Personalized Therapy Shows Feasibility in Metastatic Breast Cancer

April 13th 2021

A multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data has demonstrated feasibility in patients metastatic breast cancer vs DNA sequencing alone.

Telisotuzumab Vedotin Demonstrates Efficacy and Tolerability in Previously Treated c-MET+ NSCLC

April 13th 2021

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer.

Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations

April 13th 2021

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

D-0316 Shows Encouraging Efficacy in EGFR T790M+ NSCLC Subsets

April 12th 2021

Treatment with D-0316 demonstrated encouraging clinical activity in select patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior therapy.

Twice-Daily Poziotinib Improves Efficacy, Tolerability in EGFR- or HER2 Exon 20–Positive NSCLC

April 12th 2021

Administering the investigational TKI poziotinib at a twice-daily dose compared with once-daily dosing showed a reduction in both grade 3 or higher treatment emergent adverse effects and dose interruptions, as well as improved efficacy in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Talazoparib Plus Carboplatin Induces Synergistic Activity in Multiple TNBC Cell Lines

April 12th 2021

The combination of the PARP inhibitor talazoparib and carboplatin demonstrated synergistic activity in 7 cell lines of triple-negative breast cancer, with greater DNA damage and cell death observed in PARP inhibitor–resistant cell lines and at lower concentrations of talazoparib when combined with carboplatin.

Dabrafenib Plus Trametinib Provides Benefit Across Glioma Subtypes

April 12th 2021

Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.

Dr. Gorlick on the Use of Integrative Surfaceome Profiling to Identify Targets in Osteosarcomas

April 12th 2021

Richard Gorlick, MD, discussed results from a study examining the use of integrative surfaceome profiling to identify immunotherapeutic targets in patients with osteosarcomas.

Adavosertib/Irinotecan Shows Early Activity in Pediatric Neuroblastoma

April 12th 2021

Adavosertib plus irinotecan showed early activity in a cohort of pediatric patients with neuroblastoma, thus meeting the protocol-defined efficacy end point of the 1/2 ADVL1312 trial.

x